IP Library Patent Application 18416505
Patent Application
App. No. 18/416,505

DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF ABNORMAL TISSUE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/416,505
Abstract

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.

Claims (10)

1 . A method of treating a patient having a mass of undesired tissue, the method comprising:

advancing a distal end of an instrument into a luminal structure of a body of the patient, wherein the instrument includes an energy delivery body disposed near its distal end, wherein the energy delivery body is configured deliver pulsed electric field energy toward the mass of undesired tissue;

positioning a return electrode on the patient;

delivering the pulsed electric field energy in a monopolar fashion so as to utilize the return electrode; and

delivering an additional therapy to the patient, wherein the additional therapy comprises radiotherapy, chemotherapy, immunotherapy, targeted therapy, focal therapy, gene therapy, plasmid therapy, or a combination of any of these.

2 . A method as in claim 1 , wherein delivering the pulsed electric field energy occurs prior to delivering the additional therapy.

3 . A method as in claim 1 , wherein delivering the pulsed electric field energy occurs after delivering the additional therapy.

4 . A method as in claim 1 , wherein delivering the pulsed electric field energy occurs during a treatment session of delivering the additional therapy.

5 . A method as in claim 1 , wherein the additional therapy comprises chemotherapy, and wherein delivering the pulsed electric field energy comprises delivering sufficient pulsed electric field energy to synergistically increase the effect of the chemotherapy.

6 . A method as in claim 1 , wherein the delivering of the pulsed electric field energy comprises delivering the pulsed electric field energy in a manner which causes an abscopal effect by the patient.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2026
From: GLEIMAN, SETH S.; MERCER, NICHOLAS S.; O'BRIEN, TIMOTHY J.; WALDSTREICHER, JONATHAN R.; TAYLOR, KEVIN J.; MANGUAL ARBELO, LUIS L.; NEAL, ROBERT E., II; KRIMSKY, WILLIAM SANFORD; CASTELLVI, QUIM
To: GALARY, INC.
Reel/Frame 073585/0602 →
CHANGE OF NAME Recorded Jan 26, 2026
From: GALARY, INC.
To: GALVANIZE THERAPEUTICS, INC.
Reel/Frame 073585/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2026
From: PASTORI, CHIARA; NAFIE, EBTESAM; WAGH, MUKTA S.
To: GALVANIZE THERAPEUTICS, INC.
Reel/Frame 073585/0747 →
SECURITY INTEREST Recorded Jan 13, 2025
From: GALVANIZE THERAPEUTICS, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC
Reel/Frame 069879/0694 →